Werewolf Therapeutics Stock Current Liabilities
| HOWL Stock | USD 1.00 0.13 14.56% |
Fundamental analysis of Werewolf Therapeutics allows traders to better anticipate movements in Werewolf Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Non Current Liabilities Other is expected to rise to about 15.2 M this year, although the value of Total Current Liabilities will most likely fall to about 14.3 M. Werewolf | Current Liabilities | Build AI portfolio with Werewolf Stock |
Werewolf Therapeutics Company Current Liabilities Analysis
Werewolf Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Werewolf Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Werewolf Therapeutics is extremely important. It helps to project a fair market value of Werewolf Stock properly, considering its historical fundamentals such as Current Liabilities. Since Werewolf Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Werewolf Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Werewolf Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Werewolf Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Werewolf Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Werewolf Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Werewolf Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Werewolf Therapeutics could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics of similar companies.Werewolf Therapeutics is currently under evaluation in current liabilities category among its peers.
Werewolf Fundamentals
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 14.08 M | ||||
| Shares Outstanding | 48.54 M | ||||
| Shares Owned By Insiders | 5.61 % | ||||
| Shares Owned By Institutions | 45.89 % | ||||
| Number Of Shares Shorted | 902.85 K | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 52.22 X | ||||
| Revenue | 1.89 M | ||||
| Gross Profit | (50.48 M) | ||||
| EBITDA | (64.05 M) | ||||
| Net Income | (70.52 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 37.09 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (56.19 M) | ||||
| Short Ratio | 0.72 X | ||||
| Earnings Per Share | (1.62) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 6.17 | ||||
| Number Of Employees | 39 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 42.39 M | ||||
| Total Asset | 126.93 M | ||||
| Retained Earnings | (414.59 M) | ||||
| Working Capital | 97.89 M | ||||
| Net Asset | 126.93 M |
About Werewolf Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Werewolf Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Werewolf Therapeutics Piotroski F Score and Werewolf Therapeutics Altman Z Score analysis. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.